Evaluation of sex differences in cannabinoid dependence

Drug and Alcohol Dependence

Volumn 137, Issue 1, 2014, Pages 20-28

  Marusich, Julie A ^a   Lefever, Timothy W ^a   Antonazzo, Kateland R ^a   Craft, Rebecca M ^b   Wiley, Jenny L ^a  

^a RTI INTERNATIONAL   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Dependence; Rimonabant; Sex differences

Indexed keywords

11 HYDROXYDRONABINOL; RIMONABANT; CANNABINOID; DRONABINOL;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANNABINOID DEPENDENCE; COGNITION; CONTROLLED STUDY; DRUG DEPENDENCE; ESTRUS CYCLE; FEMALE; HEAD TWITCH; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; SPRAGUE DAWLEY RAT; STARTLE REFLEX; TREMOR; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; ANIMAL; AUDITORY STIMULATION; DRUG EFFECTS; EVALUATION STUDY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; RANDOMIZATION; SENSORY GATING; SEXUAL DEVELOPMENT; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

ANIMALIA; CANNABIS SATIVA; RATTUS; RODENTIA;

ACOUSTIC STIMULATION; ANIMALS; CANNABINOIDS; DRONABINOL; FEMALE; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SENSORY GATING; SEX CHARACTERISTICS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 84896064529     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.01.019     Document Type: Article

References (62)

1. Aceto M.D., Scates S.M., Lowe J.A., Martin B.R. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J. Pharmacol. Exp. Ther. 1996, 278:1290-1295.
2. Aggarwal S.K., Carter G.T., Sullivan M.D., ZumBrunnen C., Morrill R., Mayer J.D. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J. Opioid Manag. 2009, 5:153-168.
3. Andrews C.D., Fernando J.C., Curzon G. Differential involvement of dopamine-containing tracts in 5-hydroxytryptamine-dependent behaviours caused by amphetamine in large doses. Neuropharmacology 1982, 21:63-68.
4. Ayalon D., Nir I., Cordova T., Bauminger S., Puder M., Naort Z., Kashi R., Zor U., Harell A., Lindner H.R. Acute effect of delta1-tetrahydrocannabinol on the hypothalamo-pituitary-ovarian axis in the rat. Neuroendocrinology 1977, 23:31-42.
5. Barbui C., Nose M., Bindman J., Schene A., Becker T., Mazzi M.A., Kikkert M., Camara J., Born A., Tansella M. Sex differences in the subjective tolerability of antipsychotic drugs. J. Clin. Psychopharmacol. 2005, 25:521-526.
6. Bass C.E., Griffin G., Grier M., Mahadevan A., Razdan R.K., Martin B.R. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacol. Biochem. Behav. 2002, 74:31-40.
7. Bass C.E., Martin B.R. Time course for the induction and maintenance of tolerance to delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend. 2000, 60:113-119.
8. Beardsley P.M., Balster R.L., Harris L.S. Dependence on tetrahydrocannabinol in rhesus monkeys. J. Pharmacol. Exp. Ther. 1986, 239:311-319.
9. Beardsley P.M., Martin B.R. Effects of the cannabinoid CB(1) receptor antagonist SR 141716A, after delta(9)-tetrahydrocannabinol withdrawal. Eur. J. Pharmacol. 2000, 387:47-53.
10. Becker J.B., Hu M. Sex differences in drug abuse. Front. Neuroendocrinol. 2008, 29:36-47.
11. Bortolato M., Aru G.N., Frau R., Orru M., Luckey G.C., Boi G., Gessa G.L. The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology (Berl.) 2005, 177:264-271.
12. Carroll M.E., Lynch W.J., Roth M.E., Morgan A.D., Cosgrove K.P. Sex and estrogen influence drug abuse. Trends Pharmacol. Sci. 2004, 25:273-279.
13. Compton D.R., Dewey W.L., Martin B.R. Cannabis dependence and tolerance production. Adv. Alcohol Subst. Abuse 1990, 9:129-147.
14. Cook S.A., Lowe J.A., Martin B.R. CB1 receptor antagonist precipitates withdrawal in mice exposed to delta9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 1998, 285:1150-1156.
15. Craft R.M., Marusich J.A., Wiley J.L. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?. Life Sci. 2013, 92:476-481.
16. Craft R.M., Wakley A.A., Tsutsui K.T., Laggart J.D. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat. J. Pharmacol. Exp. Ther. 2013, 340:787-800.
17. Curzon G., Fernando J.C., Lees A.J. Backward walking and circling: behavioural responses induced by drug treatments which cause simultaneous release of catecholamines and 5-hydroxytryptamine. Br. J. Pharmacol. 1979, 66:573-579.
18. Davis M., Strachan D.I., Kass E. Excitatory and inhibitory effects of serotonin on sensorimotor reactivity measured with acoustic startle. Science 1980, 209:521-523.
19. Dawbarn D., Long S.K., Pycock C.J. Increased central 5-hydroxytryptamine receptor mechanisms in rats after chronic neuroleptic treatment. Br. J. Pharmacol. 1981, 73:149-156.
20. Diana M., Melis M., Muntoni A.L., Gessa G.L. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:10269-10273.
21. Falenski K.W., Thorpe A.J., Schlosburg J.E., Cravatt B.F., Abdullah R.A., Smith T.H., Selley D.E., Lichtman A.H., Sim-Selley L.J. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology 2010, 35:1775-1787.
22. Fattore L., Spano M.S., Altea S., Angius F., Fadda P., Fratta W. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br. J. Pharmacol. 2007, 152:795-804.
23. Ferrari F., Ottani A., Giuliani D. Inhibitory effects of the cannabinoid agonist HU210 on rat sexual behavior. Physiol. Behav. 2000, 69:547-554.
24. 9-tetrahydrocannabinol develops during chronic prepubertal treatment of female rats. J. Pharmacol. Exp. Ther. 1986, 238:1034-1038.
25. Freeman M.E. The ovarian cycle of the rat. The Physiology of Reproduction 1988, 1893-1928. Raven Press, New York, NY. E. Knobil, J. Neill (Eds.).
26. Gonzalez S., Fernandez-Ruiz J., Di Marzo V., Hernandez M., Arevalo C., Nicanor C., Cascio M.G., Ambrosio E., Ramos J.A. Behavioral and molecular changes elicited by acute administration of SR 141716 to delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. Drug Alcohol Depend. 2004, 74:159-170.
27. Gorelick D.A., Levin K.H., Copersino M.L., Heishman S.J., Liu F., Boggs D.L., Kelly D.L. Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend. 2012, 123:141-147.
28. Haney M., Ward A.S., Comer S.D., Foltin R.W., Fischman M.W. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl.) 1999, 141:395-404.
29. Harte-Hargrove L.C., Dow-Edwards D.L. Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety. Behav. Brain Res. 2012, 231:48-59.
30. Hasin D.S., Keyes K.M., Alderson D., Wang S., Aharonovich E., Grant B.F. Cannabis withdrawal in the United States: results from NESARC. J. Clin. Psychiatry 2008, 69:1354-1363.
31. Hill A.J., Williams C.M., Whalley B.J., Stephens G.J. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol. Ther. 2012, 133:79-97.
32. Hoffman H.S., Ison J.R. Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol. Rev. 1980, 87:175-189.
33. Huang P., Liu-Chen L.Y., Kirby L.G. Anxiety-like effects of SR 141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze. Neurosci. Lett. 2010, 475:165-168.
34. Kostellow A.B., Ziegler D., Kunar J., Fujimoto G.I., Morrill G.A. Effect of cannabinoids on estrous cycle, ovulation and reproductive capacity of female A/J mice. Pharmacology 1980, 21:68-75.
35. Kritzer M.F., Creutz L.M. Region and sex differences in constituent dopamine neurons and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical projections in rats. J. Neurosci. 2008, 28:9525-9535.
36. Leussis M.P., Bolivar V.J. Habituation in rodents: a review of behavior, neurobiology, and genetics. Neurosci. Biobehav. Rev. 2006, 30:1045-1064.
37. Levin K.H., Copersino M.L., Heishman S.J., Liu F., Kelly D.L., Boggs D.L., Gorelick D.A. Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend. 2010, 111:120-127.
38. Lichtman A.H., Fisher J., Martin B.R. Precipitated cannabinoid withdrawal is reversed by delta(9)-tetrahydrocannabinol or clonidine. Pharmacol. Biochem. Behav. 2001, 69:181-188.
39. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 1991, 40:471-478.
40. Melis M., Perra S., Muntoni A.L., Pillolla G., Lutz B., Marsicano G., Di Marzo V., Gessa G.L., Pistis M. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J. Neurosci. 2004, 24:10707-10715.
41. Mendelson J.H., Mello N.K., Ellingboe J., Skupny A.S., Lex B.W., Griffin M. Marihuana smoking suppresses luteinizing hormone in women. J. Pharmacol. Exp. Ther. 1986, 237:862-866.
42. National Research Council Guidelines for the care and use of mammals in neuroscience and behavioral research 2011, National Academies Press, Washington, DC.
43. O'Connell M.E., Morrill G.A., Fujimoto G.I., Kostellow A.B. Factors affecting the response of the female rat reproductive system to cannabinoids. Toxicol. Appl. Pharmacol. 1987, 88:411-417.
44. Patel S., Rademacher D.J., Hillard C.J. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J. Pharmacol. Exp. Ther. 2003, 306:880-888.
45. Schlosburg J.E., O'Neal S.T., Conrad D.H., Lichtman A.H. CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action. Psychopharmacology (Berl.) 2011, 216:323-331.
46. Schneider M., Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003, 28:1760-1769.
47. Schreiner A.M., Dunn M.E. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp. Clin. Psychopharmacol. 2012, 20:420-429.
48. 9-tetrahydrocannabinol on primate menstrual cycle. Science 1983, 219:1453-1455.
49. Spiga S., Lintas A., Diana M. Altered mesolimbic dopamine system in THC dependence. Curr. Neuropharmacol. 2011, 9:200-204.
50. Substance Abuse and Mental Health Services Administration Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, in NSDUH Series H-46, HHS Publication No. (SMA) 13-4795 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD.
51. Swerdlow N.R., Braff D.L., Geyer M.A. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav. Pharmacol. 2000, 11:185-204.
52. Tanda G., Loddo P., Di Chiara G. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur. J. Pharmacol. 1999, 376:23-26.
53. Thornton-Jones Z.D., Kennett G.A., Benwell K.R., Revell D.F., Misra A., Sellwood D.M., Vickers S.P., Clifton P.G. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol. Biochem. Behav. 2006, 84:353-359.
54. Tseng A.H., Craft R.M. Sex differences in antinociceptive and motoric effects of cannabinoids. Eur. J. Pharmacol. 2001, 430:41-47.
55. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 1995, 280:R13-R15.
56. Walker Q.D., Ray R., Kuhn C.M. Sex differences in neurochemical effects of dopaminergic drugs in rat striatum. Neuropsychopharmacology 2006, 31:1193-1202.
57. Walsh D., Nelson K.A., Mahmoud F.A. Established and potential therapeutic applications of cannabinoids in oncology. Support. Care Cancer 2003, 11:137-143.
58. Wiley J.L., Burston J.J., Leggett D.C., Alekseeva O.O., Razdan R.K., Mahadevan A., Martin B.R. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br. J. Pharmacol. 2005, 145:293-300.
59. Wiley J.L., Walentiny M.D., Vann R.E., Baskfield C.Y. Dissimilar cannabinoid substitution patterns in mice trained to discriminate delta(9)-tetrahydrocannabinol or methanandamide from vehicle. Behav. Pharmacol. 2011, 22:480-488.
60. Wiley J.L., O'Connell M.M., Tokarz M.E., Wright M.J. Pharmacological effects of acute and repeated administration of {delta}9-tetrahydrocannabinol in adolescent and adult rats. J. Pharmacol. Exp. Ther. 2007, 320:1097-1105.
61. Williamson E.M., Evans F.J. Cannabinoids in clinical practice. Drugs 2000, 60:1303-1314.
62. Wise L.E., Varvel S.A., Selley D.E., Wiebelhaus J.M., Long K.A., Middleton L.S., Sim-Selley L.J., Lichtman A.H. Delta(9)-tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory. Psychopharmacology (Berl.) 2011, 217:485-494.